当前时代乳腺近距离放疗补量的价值:GEC-ESTRO乳腺癌工作组叙述性文献综述
该叙述性综述通过检索1984至2025年112篇文献,评估在超分割和同步整合补量广泛应用的背景下,间质近距离放疗补量在乳腺癌治疗中的角色。综述更新了高危因素与患者选择标准,并比较了补量技术,提出近距离放疗补量仍适用于特定高危患者,可实现靶区剂量提升同时保护危及器官。
要点
- 年龄<40岁、切缘阳性者强烈推荐补量。
- 年龄<50岁且伴高级别、广泛导管内癌或三阴性表型者强烈推荐补量。
- 间质近距离放疗可高剂量覆盖靶区并显著降低危及器官剂量。
核心结论
- 近距离放疗补量在同步整合补量和超分割时代虽使用减少,但对特定高危乳腺癌患者仍是可实现风险适配剂量提升并保护危及器官的有价值选择。
研究设计与样本
- GEC-ESTRO乳腺癌工作组开展的叙述性文献综述,检索PubMed、MEDLINE和Cochrane数据库1984至2025年间文献,共纳入112篇文章。
主要发现
- 补量应强烈推荐用于年龄<40岁、切缘阳性、以及年龄<50岁且伴高级别疾病、广泛导管内癌和/或三阴性表型中至少一项特征的患者。
- 其他情形包括新辅助化疗后残留病灶,应进行平衡的共同决策。
- 间质近距离放疗可将高辐射剂量递送至靶区,同时显著降低邻近危及器官接受的剂量。
关键数值与推荐
- 年龄<40岁:强烈推荐补量。
- 切缘阳性:强烈推荐补量。
- 年龄<50岁且伴高级别疾病、广泛导管内癌和/或三阴性表型中至少一项:强烈推荐补量。
- 新辅助化疗后残留病灶等其他情形:平衡的共同决策。
临床怎么用
- 对年龄<40岁、切缘阳性、或年龄<50岁且伴高级别/广泛导管内癌/三阴性表型的患者,应强烈推荐补量。
- 对其他情形包括新辅助化疗后残留病灶,应与患者共同决策是否补量。
- 间质近距离放疗可作为高危患者补量技术选择,以实现靶区剂量提升并保护危及器官。
局限性
- 本文为叙述性文献综述,非系统评价或荟萃分析,未提供定量合并效应量。
- 检索截至2025年,纳入文献112篇,未报告样本量、P值等定量数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify patients who may benefit from an interstitial brachytherapy boost in the era of hypofractionation and widespread use of simultaneous integrated boost. MATERIAL AND METHODS: Between 1984 and 2025, 112 articles were identified through a narrative search of the PubMed, MEDLINE, and Cochrane databases using the keywords "breast cancer", "boost", "interstitial brachytherapy", and "interventional radiotherapy". Two main areas were addressed: an update on risk factors and patient selection, and a review of boost techniques, with an emphasis on interstitial brachytherapy and comparisons with other techniques. Based on this evidence, we formulated recommendations on the role of brachytherapy boost in contemporary breast cancer (BC) treatment. RESULTS: Based on the available literature, the addition of a boost should be strongly recommended for patients aged <40 years, patients with positive margins, and patients aged <50 years with at least one of the following features: high-grade disease, extensive intraductal carcinoma, and/or a triple-negative phenotype. In other scenarios, including residual disease after neoadjuvant chemotherapy, a balanced shared decision should be made. Interstitial brachytherapy allows delivery of a high radiation dose to the target volume while significantly reducing the dose received by adjacent organs at risk. CONCLUSION: The use of brachytherapy as a boost has declined, particularly since the introduction of integrated and ultra-hypofractionated regimens. In the current era of breast cancer treatment, we suggest that brachytherapy remains a valuable option for selected high-risk patients because it enables dose escalation tailored to the risk volume while sparing surrounding organs at risk.
引用
- Montesinos IM, Konat-Bąska K, Guinot JL, et al. The value of breast brachytherapy boost in the current era: a narrative literature review from the GEC-ESTRO breast cancer working group. Clin Transl Radiat Oncol. 2026. PMID: 42921130. doi:10.1016/j.ctro.2026.101324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。